|
|
|
| |
 |
|
|
|
推薦指數：
|
|
- 內容介紹
|
Atlas of Clinical Positron Emission Tomography - With Imaging Correlation
By Michael S. Kipper, MD and Marie Tartar, MD
Approx. 514 pages, Approx. 1100 illustrations, Copyright 2004
Description
This user-friendly atlas demonstrates all of the major clinical applications of PET scanning. Its case-based approach—with teaching points, pitfalls, and "mimics"—presents all of the material in a concise and practical manner. And, correlative cross-sectional images illustrate the clinical features depicted in PET findings.
Key Features
Demonstrates the advantages and limitations of PET imaging in the investigation of cancer, neurological disorders, myocardial viability, and more.
Delivers more than 1,100 state-of-the-art images of outstanding quality.
Offers correlative plain film, MR, CT, ultrasound, and nuclear imaging studies to help readers recognize what various PET findings depict.
Captures the wide range of normal and pathologic PET findings seen in all relevant body areas, and points out the many interpretation pitfalls, including normal and benign variants.
Table of Contents
Table of Contents Chapter 1: The Basics of PET Chapter 2: Approach to PET Image Interpretation, Normal Variants, and Benign Processes Chapter 3: Lung Cancer Case 1: SPN, positive, no other disease sites (proven adenocarcinoma). Case 2: SPN, positive (proven adenocarcinoma). Case 3: SPN, positive (proven recurrent squamous cell carcinoma). Case 4: SPN, positive (proven large cell carcinoma). Case 5: SPN, positive (proven squamous cell carcinoma). Case 6: SPN, negative, tuberculoma. Case 7: SPN, negative, aspergillosis. Case 8: SPN, negative, cocci granuloma. Case 9: SPN-positive, with hilar and/or mediastinal disease (proven large cell carcinoma). Case 10: SPN, positive, with false positive mediastinal disease (proven squamous cell carcinoma). Case 11: SPN-positive, with hilar and/or mediastinal disease (advanced aquamous cell carcinoma). Case 12: Lung cancer staging, primary positive, no other disease (large cell undifferentiated carcinoma). Case 13: Lung cancer staging, primary positive (proven adenocarcinoma). Case 14: Lung cancer staging, primary only positive (NSCLC), coexisting infiltrative lung disease. Case 15: Lung cancer staging, primary site only positive (proven squamous cell carcinoma). Case 16: Lung cancer staging, with subtle mediastinal involvement (squamous cell carcinoma). Case 17: Non-small cell lung cancer, with mediastinal involvement. Case 18: Lung cancer staging, with mediastinal disease (large cell carcinoma). Case 19: Lung cancer staging, with bone metastasis (adenocarcinoma). Case 20: Lung cancer staging, with bone metastases (large cell malignancy). Case 21: Lung cancer staging, Stage IV non-small cell lung cancer, with adrenal metastasis. Case 22: Lung cancer, restaging post-treatment, with adrenal metastasis (large cell carcinoma). Case 23: Squamous cell carcinoma, Stage IV, with axillary node involvement. Case 24: Lung cancer (SCC), with chest wall invasion. Case 25: Known lung cancer for staging, extensive disease (squamous cell carcinoma). Case 26: Lung cancer staging, extensive disease (NSCLC). Case 27: Lung cancer staging, small cell carcinoma. Case 28: Lung cancer staging, localized pleural involvement (NSCLC and adenocarcinoma). Case 29: Lung cancer staging, pleural adenocarcinoma. Case 30: Non-small cell lung carcinoma, metastatic to pleura. Case 31: Lung cancer restaging, treatment assessment (SCC). Case 32: Lung cancer restaging, radiation therapy effects (SCC). Case 33: Bilateral lung cancers. Case 34: Breast carcinoma pulmonary metastases mimicking synchronous lung cancers. Case 35: Bilateral lung cancers. Case 36: Pitfall: Bronchoalveolar cell carcinoma. Case 37: Pitfall: Bronchoalveolar cell carcinoma. Case 38: Pitfall: Bronchoalveolar cell carcinoma. Case 39: Pitfall: Lung cancer false positive, pulmonary infarct. Case 40: Pitfall: lung cancer false positive, active tuberculosis. Case 41: Pitfall: lung cancer false positive, sarcoidosis. Case 42: Pitfall: Lung cancer, size limitation. Kipper – Table of Contents – page 2 Chapter 4: Lymphoma Case 1: Lymphoma, limited stage disease, staging. Case 2: Lymphoma, staging, isolated neck disease. Case 3: Lymphoma, staging and treatment assessment, pulmonary parenchymal involvement. Case 4: Unexpected PET identification of limited stage visceral lymphoma. Case 5: Bulky thoracic NSHD, initial staging and residual mass treatment assessment. Case 6: Thoracic HD, initial staging and treatment assessment. Case 7: Thoracic and abdominal HD: initial staging, treatment assessment, marrow activation. Case 8: Lymphoma, nodal & visceral involvement, staging & treatment assessment, marrow activation. Case 9: Recurrent lymphoma, bone marrow involvement. Case 10: Recurrent pelvic NHL, radiation therapy follow-up. Case 11: Mantle cell lymphoma, radiation response. Case 12: Mediastinal recurrent lymphoma, response to chemotherapy. Case 13: Mesenteric NHL, residual mass assessment. Case 14: Lymphoma, staging & treatment assessment, head & neck presentation. Case 15: Recurrent lymphoma, pediatric patient. Case 16: Lymphoma follow-up, thymic rebound. Chapter 5: Melanoma Case 1: Staging, persistent disease at operative site Case 2: Initial and re-staging, disease progression despite chemotherapy. Case 3: Staging, unexpected additional disease site. Case 4: Staging, multiple unexpected additional disease sites. Case 5: Melanoma, restaging, solitary recurrent disease site (axilla). Case 6: Restaging, recurrent facial disease. Case 7: Restaging, progressive facial recurrences. Case 8: Melanoma, restaging, lung and brain metastases. Case 9: Restaging; lung, hilar, liver and osseous metastases. Case 10: Restaging, extensive disease, treatment assessment. Case 11: Restaging, advanced disease (carcinomatosis). Chapter 6: Colorectal Cancer Case 1: Initial staging, no additional disease site (rectal cancer). Case 2: Initial staging, involved adjacent lymph node. Case 3: Initial staging, distant metastases. Case 4: Restaging, solitary liver metastasis. Case 5: Restaging, recurrent hepatic metastasis. Case 6: Restaging, solitary liver metastasis. Case 7: Restaging, retroperitoneal nodal recurrence, assessment of post-treatment pre-sacral mass. Case 8: Restaging, pelvic recurrences. Case 9: Restaging, pre-sacral recurrence. Case 10: Restaging, pulmonary parenchymal and pleural recurrences. Case 11: Recurrent colorectal carcinoma, rising CEA, bone metastases. Case 12: Colon cancer, liver metastasis, treatment effect (RF ablation). Case 13: Liver metastasis, assessment of RF ablation efficacy. Case 14: Liver metastases, surgical and interventional treatment effects. Case 15: Liver metastases, chemotherapy efficacy. Case 16: Pitfall: Recurrence, sub-centimeter lung metastases. Case 17: Pitfall: Coexisting benign disease (viral axillary adenitis). Chapter 7: Other Gastrointestinal Cancers Case 1: Proximal esophageal squamous cell carcinoma. Case 2: Distal esophageal adenocarcinoma, with gastro-hepatic nodal involvement. Case 3: Esophageal carcinoma, superior mediastinal paraesophageal nodal involvement. Case 4: Distal esophageal SCC. Case 5: Distal esophageal adenocarcinoma, with gastric cardia extension and paragastric nodal involvement. Case 6: Gastric carcinoma, with retroperitoneal nodal metastases. Case 7: Gastric carcinoma, with peritoneal carcinomatosis. Case 8: Pancreatic adenocarcinoma. Kipper – Table of Contents – page 3 Case 9: Locally recurrent pancreatic carcinoma. Case 10: Recurrent pancreatic carcinoma, metastatic to liver and brain. Case 11: Ampullary adenocarcinoma, with local nodal involvement. Case 12: Cholangiocarcinoma, with liver metastasis. Case 13: Recurrent cholangiocarcinoma, drop metastasis. Case 14: Suspected residual gallbladder carcinoma. Chapter 8: Head and Neck Cancer Case 1: Normal head and neck anatomy example. Case 2: Glottic squamous cell carcinoma, initial diagnosis. Case 3: Initial staging, BOT squamous cell carcinoma, with nodal metastasis at presentation. Case 4: Locally advanced base of tongue squamous cell carcinoma, with bilateral necrotic lymph node metastases. Case 5: Metastatic squamous cell carcinoma, cervical lymph node presentation, primary lesion search. Case 6: Hard palate squamous cell carcinoma, radiation therapy planning. Case 7: Recurrent maxillary non-small cell malignancy. Case 8: Recurrent and progressive squamous cell carcinoma. Case 9: Nasopharyngeal squamous cell carcinoma, with bone metastases. Case 10: Squamous cell carcinoma, metastatic to thoracic spine, incipient cord compression presentation. Chapter 9: Breast Cancer Case 1: Focal breast activity due to an unsuspected breast cancer. Case 2: Breast cancer, initial staging, axillary nodal presentation, primary search and internal mammary adenopathy. Case 3: Breast cancer restaging, normal post-lumpectomy and radiation breast findings. Case 4: Post surgical biopsy scar, post lumpectomy for infiltrating ductal carcinoma. Case 5: Treated inflammatory breast cancer. Case 6: Recurrent inflammatory breast cancer. Case 7: Breast cancer restaging, in situ neoadjuvantly treated infiltrating lobular carcinoma, with diffuse blastic bone metastases. Case 8: Breast cancer restaging, bone metastases. Case 9: Breast cancer restaging, active bone metastases, treated liver metastases. Case 10: Recurrent breast cancer, with extensive liver metatases. Case 11: Breast cancer restaging, solitary liver metatasis. Case 12: Recurrent breast cancer, with chest wall and lung parenchymal disease. Case 13: Breast cancer restaging, axillary and chest wall involvement and bone metastases. Case 14: Breast cancer restaging, extensive local and nodal recurrence. Case 15: Breast cancer restaging, local and nodal recurrences in axilla, supraclavicular neck and mediastinum. Case 16: Breast cancer restaging; mediastinal, neck and supraclavicular nodal recurrences. Case 17: Breast cancer restaging, hilar nodal involvement, progression to liver and bone metastases. Case 18: Restaging, thoracic (nodal and pulmonary parenchymal) metastases. Case 19: Breast Cancer restaging, assessment of chemotherapy efficacy, mediastinal and bone metastases. Chapter 10: Miscellaneous Tumors Case 1: Recurrent thyroid carcinoma, lungs and neck. Case 2: Recurrent thyroid carcinoma, isolated neck lymph node. Case 3: Recurrent thyroid carcinoma to neck, low metabolic rate. Case 4: Pitfall: Suspected recurrent thyroid carcinoma to mediastinum, false positive (thymus) Case 5: In situ primary, presenting with pleural metastases Case 6: Sarcomatoid renal cell carcinoma, with retroperitoneal metastases Case 7: In situ primary, with IVC tumor extension Case 8: Renal cell carcinoma, lung metastasis. Case 9: Recurrent renal cell carcinoma, hilar and vertebral metastases Case 10: Locally recurrent clear cell renal cell carcinoma, with lung metastases Case 11: Widely metastatic testicular carcinoma, response to chemotherapy Case 12: Suspected recurrence, disseminated sarcoidosis Kipper – Table of Contents – page 4 Case 13: In situ primary transitional cell carcinoma Case 14: Widely metastatic transitional cell carcinoma Case 15: Widely metastatic prostate cancer, dedifferentiated Case 16: Benign adrenal hemangioendothelioma Case 17: Recurrent ovarian carcinoma, response to chemotherapy Case 18: Recurrent ovarian carcinoma, with parathyroid adenoma Case 19: Local recurrence of cervical carcinoma, pararectal region with synchronous lung colon carcinoma metastasis Case 20: Widely metastatic cervical carcinoma (brain, porta hepatic, supraclavicular and presacral) Case 21: Uterine corpus carcinoma, with vaginal metastasis Case 22: Unsuspected recurrent leiomyosarcoma to multiple muscles Case 23: Synovial sarcoma, metastatic to lung Case 24: Recurrent intraabdominal leiomyosarcoma Case 25: Recurrent thoracic liposarcoma Case 26: Ewing’s sarcoma follow-up Case 27: Residual leiomyosarcoma, post operative evaluation for residual disease Case 28: Malignant thymoma, pleural recurrence Case 29: Pitfall: Inflammatory reaction, suspected anterior mediastinal thymoma Case 30: Multiple myeloma, initial staging Case 31: Multiple discrete lesions, known disease follow-up Case 32: Multiple myeloma, diffusely infiltrative, poorly demonstrated on PET Case 33: Kaposi’s sarcoma (non-AIDS) Case 34: Bowen’s (multiple squamous cell carcinoma) Chapter 11: Neurologic PET Applications Case 1: Normal brain PET: guidelines for image interpretation. Case 2: Recurrent glioblastoma multiforme (differentiation from radiation necrosis). Case 3: Lung cancer metastasis, gamma knife follow-up. Case 4: Low-grade oligodendroglioma, initial diagnosis. Case 5: Oligodendroglioma, tumor differential diagnosis. Case 6: Low-grade glioma, transformation. Case 7: MCA infarct. Case 8: Radiation necrosis, residual oligodendroglioma. Case 9: Radiation necrosis, s/p scalp melanoma therapy. Case 10: Bitemporal radiation necrosis, s/p nasopharyngeal carcinoma therapy. Case 11: Temporal radiation necrosis, s/p pre-auricular basal cell carcinoma therapy, abnormal brain SPECT. Case 12: Alzheimer’s. Case 13: Alzheimer’s. Case 14: Pick’s (frontal lobe dementia). Case 15: Primary cerebellar degeneration. Case 16: Temporal lobe hypometabolism Chapter 12: Cardiac PET Applications Case 1: Myocardial viability study: Normal example Case 2: Myocardial viability study: Patient with non-Q wave MI and CHF, with abnormal thallium viability study Case 3: Myocardial viability study: Patient with known CAD, post MI and PTCA, with recurrent angina and abnormal SPECT Case 4: Myocardial viability study: Patient with chronic CHF post MI, being considered for percutaneous revascularization for fatigue and chest pain Case 5: Myocardial viability study: Nonsurgical candidate patient with recurrent symptoms, with abnormal SPECT, being considered for repeat percutaneous intervention Case 6: Myocardial viability study: Diabetic patient with multi-vessel CAD and ischemic cardiomyopathy, being considered for CABG revascularization Kipper – Table of Contents – page 6 Case 7: Myocardial viability study: Patient with prior MI, CABG, PTCA and ischemic cardiomyopathy, with matched perfusion/metabolism defects Case 8: Myocardial viability study: Patient with long-standing CAD, post multiple revascularization procedures, with persistent angina and dypnea and recurrent disease by angiography Case 9: Myocardial viability study: Diabetic, vasculopathic, high surgical risk patient, with abnormal SPECT and poor LV function, being considered for CABG
|
|
|
其他相關書藉
[ 
[ 